EP Patent

EP0887340A4 — Novel compounds and pharmaceutical use thereof

Assigned to Japan Tobacco Inc · Expires 2000-03-29 · 26y expired

What this patent protects

Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof: wherein each symbol is as define d in the specification. These compounds and salts act selectively on cannabinoid receptors, especially peripheral receptors, are reduced in the side effect…

USPTO Abstract

Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof: wherein each symbol is as define d in the specification. These compounds and salts act selectively on cannabinoid receptors, especially peripheral receptors, are reduced in the side effects against the central nervous system, and are excellent in immunomodulatory, anti-inflammatory and antiallergic activities and a nephritis curing effect, thus being useful as agonists and antagonists of cannabinoid receptors (especially peripheral cannabinoid receptors), immunomodulator, remedies for autoimmune diseases, anti-inflammatory, antiallergic, and nephritis remedy.

Drugs covered by this patent

Patent Metadata

Patent number
EP0887340A4
Jurisdiction
EP
Classification
Expires
2000-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Japan Tobacco Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.